On December 1, 2021 Accro Bioscience (Suzhou) Limited ("Accropeutics Bioscience"), a China-based leadingbiotechnology company, reported that the company has recently raised over $50 million in an oversubscribed Series B round (Press release, Accro Bioscience, DEC 1, 2021, View Source [SID1234632773]). The financing was led by HongtaiAplus with participation from South China Venture Capital, Shenzhen Capital Group, Suzhou Oriza Holdings, and others.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Accropeutics Bioscience will leverage the funds to advance clinical development, pre-clinical research and international partnerships," said Dr. Xiaohu Zhang, co-founder and CEO of Accropeutics Bioscience, "We are very pleased with the support and confidence of our current and new investors."

"We appreciate the R&D and execution capabilities of the team, and look forward to the continuous breakthroughs of Accropeutics Bioscience in the future," said Morningside.

"We are optimistic about the development of Accropeutics Bioscience," said HongtaiAplus, "We are delighted to lead this round of financing and look forward to the in-depth cooperation with Accropeutics Bioscience in the future."